论文部分内容阅读
作者采用免疫球蛋白的测定、E-花环试验、念珠菌素与结核菌素皮肤试验,对600例患恶性实体瘤的病人(生存6个月、12个月和24个月者)在治疗前及治疗后进行了一系列的免疫学观察,发现这些试验的任何一项有减弱改变时,均示预后不良,且与减弱程度成比例。联合应用几项不同的试验,对预后估计更为精确。肿瘤限于局部时,如几项试验均正常,2年生存率为87%,一项减弱,则降为43%,二项减弱则降为11%。肿瘤限于区域时,则分别为52%,12%和4%。肿瘤广泛转移时,则分别为24%,4%和0%。然而,当肿瘤广泛转移时,如各项试验属正常者,其预后并
The authors used immunoglobulin assays, E-wreath tests, candidiases, and tuberculin skin tests for 600 patients with malignant solid tumors (survivors of 6 months, 12 months, and 24 months) before treatment. After treatment and a series of immunological observations, it was found that if any of these tests had a weakening change, they all showed a poor prognosis and were proportional to the degree of attenuation. Several different trials are used in combination to estimate the prognosis more accurately. When the tumor is limited to local conditions, if several trials are normal, the 2-year survival rate is 87%, and if one is weakened, it is reduced to 43%, and the second reduction is reduced to 11%. When the tumor was limited to the area, it was 52%, 12%, and 4%, respectively. When the tumors were widely metastasized, they were 24%, 4%, and 0%, respectively. However, when the tumor is widely metastatic, if the tests are normal, the prognosis is